



ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY

Volume 2

**A. R. Genazzani, F. Petraglia,
A. Volpe and F. Facchinetti**

ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY

Volume 2

The Proceedings of Special Symposia held at the 1st Congress of the
International Society of Gynecological Endocrinology

**Edited by
A. R. Genazzani, F. Petraglia,
A. Volpe and F. Facchinetti**



The Parthenon Publishing Group
International Publishers in Science & Technology

Casterton Hall, Camforth,
Lancs, LA6 2LA, UK

120 Mill Road, Park Ridge,
New Jersey, USA

Published in the UK and Europe by
The Parthenon Publishing Group Ltd.
Casterton Hall
Carnforth, Lancs. LA6 2LA ISBN: 1-85070-208-X

Published in North America by
The Parthenon Publishing Group Inc.
120 Mill Road
Park Ridge
New Jersey, NJ, USA ISBN 0-940813-56-4

Copyright© 1988 The Parthenon Publishing Group Ltd.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the publishers.

Typeset by Lasertext Ltd., Stretford, Manchester
Printed and bound in Great Britain by
Butler & Tanner Ltd, Frome and London

List of principal contributors

R. Abbate

Clinica Medica I
Viale Morgagni 85
50134 Firenze
Italy

A.J.M. Audebert

Institute of Robert B. Greenblatt
4 rue Vauben
Bordeaux 33000
France

D. Ayalon

Timsit Institute of Reproductive
Endocrinology
Ichilov Hospital
Tel Aviv
Israel

L. Babilonti

University of Pavia
Pavia
Italy

T. Bergh

Department of Obstetrics and
Gynecology
Akademiska Sjukhuset
S-751 85 Uppsala
Sweden

G.M. Besser

The Medical College of St
Bartholomew's Hospital
West Smithfield
London
England

P. F. Bolis

University of Pavia
Pavia
Italy

F. Boselli

Department of Obstetrics and
Gynecology
University of Modena
Modena
Italy

M. Breckwoldt

Klinikum der Albert-Ludwigs-
Universität
7800 Freiburg
Hugstetter Strasse 55
West Germany

I. A. Brosens

K. U. L. -U. C. L. Hospital
St. Elisabeth
Avenue Defré 206
1180 Brussels
Belgium

C. Bulletti

Dept. of Reproductive Medicine,
University of Bologna
Via Massarenti 13
40138 Bologna
Italy

P. L. Canonico

Institute of Pharmacology
University of Catania School of Medicine
Catania
Italy

F. Cavagnini

Department of Metabolic Diseases
University of Sassari
Italy

M. Cazzola

Clinica Medica II
Policlinico San Matteo
27100 Pavia
Italy

ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY

C. Christiansen
Department of Clinical Chemistry
Glostrup Hospital
University of Copenhagen
DK-2600 Glostrup
Denmark

C. Confalonieri
Division of Obstetrics and
Gynecology
Fondazione E. S. Macchi
Varese
Italy

C. Crosti
Department of Obstetrics and
Gynecology
Magenta Hospital
Magenta (MI)
Italy

D. Dargent
Obstetrical Clinic
Hopital E. Herriott
69437 Lyon Cedex 3
France

D. De Aloisio
Department of Obstetrics and
Gynecology
Bologna University
Italy

L. de Cecco
Institute of Obstetrics & Gynecology
University of Genoa
Genoa
Italy

G. de Virgiliis
Dept. of Obstetrics & Gynecology
University of Milan
Milan
Italy

W. P. Dmowski
Dept. of Obstetrics & Gynecology
Rush Medical College
1653 West Congress Parkway
Chicago
Illinois 60612
USA

J. Drewe
Pharina Development
Sandoz Ltd
CH-4002 Basle
Switzerland

B. Düsterberg
Schering Aktiengesellschaft
Klinische Forschung
Fertilitätskontrolle
Postfach 65 03 11
D-1000 Berlin 65
West Germany

M. Elstein
Department of Obstetrics and
Gynecology
University Hospital of South
Manchester
Nell Lane
Didsbury
Manchester
M20 8LR
England

S. Faro
Section of Infectious Disease
Dept. of Obstetrics & Gynecology
Baylor College of Medicine
Houston
Texas 77030
USA

C. Ferrari
Servizio di Endocrinologia
Divisione Medica II
Ospedale Fatebenefratelli e Oftalmico
Milano
Italy

P. Fioretti
Department of Obstetrics
Pisa University
Pisa
Italy

R. C. Gaillard
Department of Medicine
University Hospital
CH-1211 Geneva 4
Switzerland

L. Giné
Dept. of Gynecology
Hospital de Bellvitge
Principes d'Espanya
Unitat Docent de Bellvitge
Barcelona Medical School
Barcelona
Spain

LIST OF PRINCIPAL CONTRIBUTORS

D. M. Hart
Div. of Obstetrics & Gynecology
Stobhill General Hospital
Glasgow
Scotland

V. M. Jasonni
Dept. of Obstetrics & Gynecology
University of Bologna
Via Massarenti 13
40138 Bologna
Italy

H. Junkermann
Dept. of Gynecologic & Obstetric
Radiology
University of Heidelberg Medical
School
6900 Heidelberg
West Germany

P. J. Keller
Department of Obstetrics and
Gynecology
University Hospital
Zurich
Switzerland

H. Kuhl
Division of Gynecologic
Endocrinology
Department of Obstetrics and
Gynecology
J.W. Goethe University
Frankfurt am Main
West Germany

M. P. Lamb
Lincoln County Hospital
Greetwell Road
Lincoln
Lincolnshire
England

M.-A. Limouzin-Lamothe
Boucicaut Hospital
Paris
France

P. W. Lücker
Institut für klinische Pharmakologie
Bobenheim
Grunstadt
West Germany

M. A. Lumsden
Department of Obstetrics and
Gynecology
University of Edinburgh Center for
Reproductive Biology
37 Chalmer Street
Edinburgh
UK

M. Mall-Haefeli
Leiterin des Sozialmedizinischen
Dienstes, der
Universitätsfrauenklinik des
Kantonsspitals
CH-4031
Basle
Switzerland

A. Marcolongo
Department of Obstetrics and
Gynecology
University of Verona
Via delle Menegone
Verona
Italy

A. Martorana
Department of Gynecology
University of Palermo
Via A. Giordano n. 3-90127
Palermo
Italy

A. M. Mattei
III Department of Obstetrics and
Gynecology
University of Milan
Italy

G. B. Melis
Dept. of Obstetrics & Gynecology
University of Pisa
Via Roma 67
56100 Pisa
Italy

U. Montemagno
Dept. of Obstetrics & Gynecology
2nd School of Medicine
University of Naples
Via Pansini 5
80131 Naples
Italy

ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY

C. Montoneri
Institute of Clinical Obstetrics and
Gynecology
University of Catania
Catania
Italy

J. Newton
Department of Obstetrics and
Gynecology
Birmingham Maternity Hospital
Edgbaston
Birmingham
B15 2TG
England

R. J. Pepperell
Department of Obstetrics and
Gynecology
University of Melbourne
Parkville 3052
Australia

T. Rabe
Department of Obstetrics and
Gynecology
Division of Gynecological
Endocrinology
University of Heidelberg
Voss-Strasse 9
6900 Heidelberg
West Germany

J. Y. Reginster
Bone Metabolism Unit
Department of Rheumatology and
Physical Medicine
University of Liege
4020 Liege
Belgium

H. Rekers
Organon International
P.O. Box 20
5340 BH Oss
The Netherlands

B. J. Riis
Department of Clinical Chemistry
Glostrup Hospital
University of Copenhagen
DK-2600 Glostrup
Denmark

J. A. Rock
Dept. of Obstetrics & Gynecology
The Johns Hopkins University
School of Medicine
600 North Wolfe Street
Baltimore
MD 21205
USA

C. Romanini
Institute of Clinical Obstetrics &
Gynecology
University of Ancona
Ancona
Italy

R. Rondanelli
Department of Pharmacology
IRCSS
San Matteo Hospital
University of Pavia
Pavia
Italy

A. Sartani
Recordati SpA
Via Civitali 1
20148 Milan
Italy

A. E. Schindler
Dept. of Gynecology &
Gynecological Oncology
University of Essen Medical School
D-4300 Essen
West Germany

K.-W. Schweppe
Dept. of Obstetrics & Gynecology
Kreiskrankenhaus Ammerland
Academic Teaching Hospital of the
University of Göttingen
Lange Strasse 38
D-2910 Westerstede
West Germany

A. E. Semprini
VI Department of Obstetrics and
Gynecology
University of Milan Medical School
Milan
Italy

LIST OF PRINCIPAL CONTRIBUTORS

B. Silvestrini
Institute of Pharmacology &
Pharmacognosy
University of Rome "La Sapienza"
Piazzale Aldo Moro 5
00185 Rome
Italy

C. Sirtori
Institute of Pharmacological Science
University of Milan
Via A. del Sarto 21
20129 Milano
Italy

S. O. Skouby
Diabetes Centre
Department of Obstetrics and
Gynecology Y
Rigshospitalet
Copenhagen and Statens
Seruminstitut
Copenhagen
Denmark

J. C. Stevenson
Cavendish Clinic
21 Wellington Road
London
NW8 9SQ
England

A. R. Storch
Department of Obstetrics and
Gynecology
University of Modena
Italy

E. J. Thomas
Dept. of Obstetrics & Gynecology
Newcastle General Hospital
Westgate Road
Newcastle-upon-Tyne
NE4 6BE
England

P. F. M. van der Heijden
Department of Obstetrics and
Gynecology
St Radboud University Hospital
Nijmegen
The Netherlands

C. A. Villee
Department of Biological Chemistry
and Molecular Pharmacology
Harvard Medical School
Boston
MA 02115
USA

A. Volpe
Institute of Obstetrics and Gynecology
University of Modena
Italy

D. von Fournier
Dept. of Gynecological & Obstetric
Radiology
University of Heidelberg Medical
School
6900 Heidelberg
West Germany

K. von Werder
Department of Medicine Innenstadt
University of Munich
8000 Munich 2
West Germany

O. Ylikorkala
First Department of Obstetrics and
Gynecology
Helsinki University Central
Hospital
Haartmaninkatu 2
SF-00290 Helsinki
Finland

L. Zichella
I Clinica Ostetrica e Ginecologica
Universita degli Studi
'La Sapienza'
00161 Roma
Italy

Contents

List of principal contributors	xv
Section 1	NEW ACTIVITIES IN THE DOPAMINE AGONIST FIELD
Chapter 1	Introduction <i>G.M. Besser</i> 3
Chapter 2	CV 205-502, a novel octahydrobenzo[g]quinoline with potent, specific and long-lasting dopamine agonist properties <i>R.C. Gaillard, J. Brownell, K. Abeywickrama and A.F. Muller</i> 5
Chapter 3	CV 205-502, a new long-acting dopamine agonist for the treatment of hyperprolactinemia: clinical experience and hormonal findings in a 3-month study in hyperprolactinemic women <i>P.F.M. van der Heijden, R. Rolland, R.E. Lappohn, R.S. Corbeij, W.B.K.M.V. de Goeij and J. Brownell</i> 19
Chapter 4	Oral and parenteral dopamine agonists: comparative effects <i>K. von Werder, J. Schopohl and G. Mehlretter</i> 27
Chapter 5	The use of two injectable long-acting bromocriptine preparations (Parlodel® LA and Parlodel® LAR, Sandoz) in patients with prolactinoma <i>F. Cavignini, C. Maraschini, M. Moro, M. de Martin, C. Invitti, A. Brunani and I. Lancranjan</i> 39
Chapter 6	Parlodel® SRO®: an oral modified release formulation of bromocriptine with improved tolerability <i>J. Drew, E. Abisch and R. Neeter</i> 51

ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY

Chapter 7	Parlodel® SRO® and prolactinomas: clinical and therapeutic aspects <i>D. Ayalon, Y. Wachsman, A. Eshel, N. Eckstein, I. Vagman and I. Luncranjan</i>	63
Chapter 8	Conclusions <i>G. M. Besser</i>	73
Section 2	RECENT ADVANCES IN THE MANAGEMENT OF ENDOMETRIOSIS	
Chapter 9	Introduction <i>J.A. Rock</i>	77
Chapter 10	Etiology, pathogenesis and natural history of endometriosis <i>K.-W. Schweppe</i>	79
Chapter 11	Immunological aspects of endometriosis <i>W.P. Dmowski, E. Radwanska, Z. Binor and I. Turunen</i>	97
Chapter 12	Endometriosis: the goal of treatment <i>M. Elstein and K. Bancroft</i>	107
Chapter 13	Overview of the mechanism of action of danazol <i>A.J.M. Audebert</i>	115
Chapter 14	Direct effects of danazol on endometriosis tissue <i>C. Bulletti, A. Galassi, M. Balducci, M.C. Gelli, V.M. Jasonni, C. Melega and C. Flamigni</i>	127
Chapter 15	New perspectives in hormonal therapy for endometriosis <i>E.J. Thomas</i>	139
Chapter 16	Pelvic endometriosis: current and future surgical techniques <i>I.A. Brosens</i>	149
Chapter 17	New concepts in the treatment of endometriosis <i>J.A. Rock</i>	157

CONTENTS

Section 3	BEYOND SYMPTOMATIC RELIEF: DANAZOL IN RECURRING FEMININE DISORDERS	
Chapter 18	Introduction <i>G.B. Melis</i>	169
Chapter 19	The role of danazol in recurring feminine disorders <i>G.B. Melis and P. Fioretti</i>	171
Chapter 20	Diagnostic techniques in benign breast disease <i>D. von Fournier, H. Junkermann, J. Heep and E. Krapfl</i>	181
Chapter 21	Classification of benign breast disease <i>H. Junkermann, D. von Fournier and E. Krapfl</i>	193
Chapter 22	Danazol for the treatment of benign breast disease <i>A.E. Schindler</i>	199
Chapter 23	Danazol (Danol) in the treatment of premenstrual tension (PMT) <i>D.M. Hart, R. Hawthorn and M. Deeny</i>	211
Chapter 24	Efficacy of danazol in the treatment of menorrhagia <i>V.M. Jasonni, C. Bulletti, S. Naldi, G. Possati, E. Di Cosmo, L. De Paoli, R. Raffelli and C. Flamigni</i>	213
Chapter 25	Danazol in menorrhagia: a double-blind placebo-controlled study <i>M.P. Lamb</i>	221
Chapter 26	Conclusion <i>G.B. Melis</i>	233
Section 4	BENZYDAMINE TOPICAL THERAPY IN GYNECOLOGY	
Chapter 27	Benzydamine: a preclinical overview <i>B. Silvestrini</i>	237

Chapter 28	Studies on the interaction of benzydamine and antibiotics on bacteria associated with vaginitis <i>S. Faro, H. Hammill, M.G. Martens, K.H. Goodrich, G.D. Riddle and L.E. Phillips</i>	247
Chapter 29	Comparison between the activities of benzydamine and metronidazole in the therapy of bacterial vaginosis <i>C. Romanini, M. Tiriduzzi, E. Manso, S. Pellonara, P. Strusi and D. Mazzoni</i>	261
Chapter 30	Study of benzydamine therapy of non-specific vaginitis <i>L. Giné, M. Ventin, J. Petit and L. Balaguero</i>	273
Chapter 31	Pains resulting from the treatment of vulvovaginal condylomatous lesions: efficacy of Opalgyné <i>D. Dargent, B. Malvoti and L. Rey</i>	291
Chapter 32	Benzydamine topical treatment of aspecific cervicovaginitis with eversion of columnar epithelium <i>L. de Cecco, G.L. Capitanio, D. Gerbaldo, M. Mannari and R. Rissone</i>	299
Chapter 33	Vaginal ecology and sexual activity: role of topical drugs in maintaining the woman's wellbeing <i>G. de Virgiliis, F. Scaglione, D. Bonato, F. Fraschini and M. Angiolillo</i>	311
Chapter 34	Topical therapy of senile vaginitis <i>U. Montemagno, G. Colace, R. Piccoli, V. Cimini and C. Nappi</i>	315
Section 5	GESTODENE: A NEW DIRECTION IN ORAL CONTRACEPTION	
Chapter 35	Introduction <i>M. Breckwoldt</i>	333
Chapter 36	Pharmacological features of gestodene in laboratory animals and man <i>B. Dülsterberg, S. Beier, W.H.F. Schneider and J. Spona</i>	335

CONTENTS

Chapter 37	Metabolic effects of gestodene-containing low-dose oral contraceptive pill <i>T. Rabe, B. Runnebaum, K. Grunwald, L. Kiesel, J. Harenberg, R. Zimmerman, W. Fiehn and H. Weicker</i>	353
Chapter 38	The hemostatic system in women taking a new gestodene-containing oral contraceptive <i>R. Abbate, S. Pinto, C. Rostagno, V. Bruni, D. Rosati, M.C. Tirindelli and G. Mariani</i>	369
Chapter 39	Comparison of the effects of gestodene and levonorgestrel on pituitary-ovarian activity and the genital tract <i>M. Elstein and E. Eyong</i>	381
Chapter 40	Biochemical and clinical results of a new low-dose oral contraceptive <i>M. Mall-Haefeli</i>	391
Chapter 41	Conclusion <i>M. Breckwoldt</i>	409
Section 6	IRON METABOLISM IN FEMALE REPRODUCTION	
Chapter 42	Estimation of body iron status and diagnosis of iron deficiency <i>M. Cazzola and E. Ascari</i>	413
Chapter 43	Oral iron therapy <i>R. Rondanelli and M.B. Regazzi</i>	421
Chapter 44	The role of transferrin and ferritin in the materno-fetal-placental unit <i>C.A. Villee and T. Okuyama</i>	427
Chapter 45	Pregnancy and iron supplementation <i>A.E. Semprini, A. Vucetich, G. Bulfoni and G. Pardi</i>	439
Chapter 46	Factors involved in the control of menstrual blood loss <i>M.A. Lumsden, S.K. Smith, I.T. Cameron, R.W. Kelly and D.T. Baird</i>	445

ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY

Section 7	FENTICONAZOLE: A NEW THERAPY FOR VAGINAL MYCOSIS	
Chapter 47	Epidemiology of vaginal mycosis and risk factors <i>F. Boselli, P. Piccinini, M.R. Carino, R.I. Agbarakwe and A.R. Genazzani</i>	459
Chapter 48	Vulvovaginal candidiasis: pathogenic and therapeutic problems <i>L. Babilonti, S. Martini and P.F. Bolis</i>	465
Chapter 49	Recurrent vaginal mycoses: diagnostic criteria <i>C. Montoneri, G. Garozzo and G. Zarbo</i>	473
Chapter 50	Fenticonazole tissue levels after vaginal administration <i>L. De Cecco, F. Gorlero, M.C. Marre' Brunenghi, P.L. Venturini, A. Sartani and S. Martini</i>	485
Chapter 51	Short-term treatment of vaginal candidiasis: results of a multi-center study <i>A. Sartani, C. Cordaro, G. Adinolfi, E. Arisi, R. Bartoloni, L. Bianchi, D. Bosi, A. Careccia, A. Cisternino, C. Confalonieri, G. Cucchia, D. Dodero, G. Dolfi, G. Elena, H. Gamper, R. Giannone, V. Marsoni, L. Massacesi, R. Ragonese, F. Romano, F. Sirimarco, G. Torre, P. Tropea and V. Valvala</i>	491
Section 8	CONTRACEPTION INTO THE NEXT DECADE: A PREVIEW TO THE YEAR 2000	
Chapter 52	Foreword <i>P.J. Keller</i>	503
Chapter 53	The new generation of monophasic oral contraceptives <i>H. Rekers and H.J. Kloosterboer</i>	505
Chapter 54	Pharmacokinetics of progestogens <i>H. Kuhl</i>	517

CONTENTS

Chapter 55	Open comparative study on the efficacy and acceptability of two new monophasic oral contraceptives <i>L. Zichella, C. Sbrignadello, A. Tomassini, A. Di Lieto, C. Montoneri, G. Zarbo, A. Rizzitiello, M. Mancone, P. Pietrobattista, G. Sertoli and G. Perrone</i>	525
Chapter 56	Desogestrel and gestodene in oral contraceptives: metabolic effects and influence on sex steroid profiles <i>S.O. Skouby, K.R. Petersen and P. Bennet</i>	535
Chapter 57	Oral contraceptives, lipid metabolism and vasoactive prostanoids <i>O. Ylikorkala</i>	545
Chapter 58	Effects of a monophasic pill containing 20 µg ethinylestradiol plus 150 µg desogestrel on coagulatory factors <i>P. Fioretti, G.B. Melis, F. Fruzzetti and C. Ricci</i>	555
Chapter 59	Contraception towards the year 2000 <i>J. Newton</i>	561
Chapter 60	Concluding remarks <i>C. Sirtori</i>	573
Section 9	NEW HORIZONS IN OSTEOPOROSIS	
Chapter 61	Introduction <i>C. Christiansen</i>	577
Chapter 62	Estrogen therapy of osteoporosis <i>C. Christiansen</i>	579
Chapter 63	Calcitonin and estrogen in the management of osteoporosis <i>J.C. Stevenson, M.P. Cust and K.F. Ganger</i>	587
Chapter 64	Intranasal calcitonin: a new horizon in prevention of early postmenopausal bone loss <i>J.Y. Reginster, D. Denis, A. Albert, R. Deroisy, M.P. Lecart, M. A. Fontaine and P. Franchimont</i>	593

Chapter 65	The effect of nasal calcitonin on postmenopausal osteoporosis <i>B.J. Riis, C. Christiansen and K. Overgaard</i>	603
Chapter 66	A review of patients' attitudes towards osteoporosis and its treatment (Italy, France and USA) <i>M.-A. Limouzin-Lamothe</i>	609
Chapter 67	The pathophysiological relation between prolactin and bone mass <i>T. Bergh</i>	617
Chapter 68	Therapeutic implications of prolactin-induced bone loss <i>R.J. Pepperell and E. Seeman</i>	625
Section 10	DIHYDROERGOCRISTINE: CLINICAL NEURO-ENDOCRINOLOGY	
Chapter 69	Dihydroergocristine-mediated inhibition of prolactin release: involvement of multiple intracellular signals <i>P.L. Canonico, F. Mailland and U. Scapagnini</i>	635
Chapter 70	Dihydroergocristine in the management of hyperprolactinemia <i>A. Volpe, A. Zanotti, A.R. Storch and F. Mailland</i>	645
Chapter 71	Clinical use of a new antiprolactinemic drug: dihydroergocristine <i>A.M. Mattei and P.G. Crosignani</i>	653
Chapter 72	Prolactin, lactation and pathological hyperprolactinemic states: the role of a partial dopamine agonist, dihydroergocristine <i>C. Ferrari</i>	661
Chapter 73	Relative bioavailability of a new dihydroergocristine (DHC) formulation in man: an indirect assessment of bioavailability <i>P.W. Lücker, N. Wetzelsberger, J. Venitz, H. Albrecht and F. Mailland</i>	666

CONTENTS

Chapter 74	Comparison between prolactin inhibition and antilactopoietic activity of ergot alkaloids in puerperium <i>C. Crosti and A. Colombo</i>	679
Chapter 75	Dihydroergocristine in prevention of lactation <i>A. Marcolongo and I. Stoppelli</i>	685
Chapter 76	Dihydroergocristine in stopping lactation: double blind study vs bromocriptine <i>D. De Aloysio, A. Roncuzzi, F. Mailland, F. Bottiglioni and A. Zanotti</i>	695
Chapter 77	Clinical and endocrine effects of dihydroergocristine in puerperium <i>A. Martorana and F. Maneschi</i>	703
Chapter 78	Treatment with dihydroergocristine in the inhibition of lactation <i>A.R. Storchi, A. Volpe, A. Zanotti and F. Mailland</i>	713
Chapter 79	Effect of dihydroergocristine on LH pulsatile release and hot flushes in postmenopausal women <i>G.B. Melis, A. Cagnacci, A.M. Paoletti, M. Gambacciani, R. Soldani, F. Mailland and P. Fioretti</i>	719
Author index		727
Subject index		731